Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

At AAIC 2025, the founder and CEO at Veravas discussed the company’s VeraBIND tau pathology blood test, highlighting its potential to detect Alzheimer disease earlier with high accuracy. [WATCH TIME: 4 minutes]

Evaluating the VeraBIND Tau Assay for Earlier Detection of Alzheimer Disease: John Forrest

Articles

Recently published study links white matter changes to cognitive decline, emphasizing the cingulum and fornix as key biomarkers for memory loss.

White Matter Microstructural Changes Linked to Declining Cognitive Performance, Memory Issues

At AAIC 2025, the chief executive officer at ALZpath discussed the growing adoption of the company’s pTau217 antibody blood test for AD research, emphasizing its potential role in early detection. [WATCH TIME: 4 minutes]

Expanding the Presence of the ALZpath Blood Test in Alzheimer Disease Research: Mike Banville

Here's some of what is coming soon to NeurologyLive® this week. 

This Week on NeurologyLive® — August 18, 2025

, has been with the team since September 2022. Follow her on Twitter 

At the 2025 ATMRD Congress, Anissa Mitchell, LCSW, chief program officer at PMD Alliance, discussed immersive, patient-focused sessions aimed at improving clinicians’ empathy, communication, and understanding of Parkinson disease and related disorders.

Building Empathy Through Patient-Centered Simulations: Perspectives From 2025 ATMRD Congress 

Medical director of CNS Clinical Development at AskBio.

The medical director of CNS Clinical Development at AskBio discussed long-term data presented at ATMRD from the company’s phase 1b assessing the investigational gene therapy AB-1005 in Parkinson disease. [WATCH TIME: 6 minutes]  

Overviewing 36-Month, Phase 1b Data Testing Gene Therapy AB-1005 in Parkinson Disease: Nisha Chhabria MD, FAAN

At AAIC 2025, Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, discussed the association between long sleep duration, specific sleep phenotypes, and progressive cognitive decline in Hispanic populations.

Measuring Sleep Duration and Identifying Phenotypes Linked to Cognitive Decline in Hispanic Populations

The clinical assistant professor in movement disorders at Jefferson Health outlined a patient-centered, lifestyle-first approach to managing Parkinson nonmotor symptoms. [WATCH TIME: 4 minutes]

Addressing Constipation, Sleep, and Fatigue in Parkinson Disease Care: Alexa Dessy, MD

The movement disorders condition center is a resource for clinical news on the diagnosis, treatment, and management of movement disorders. | NeurologyLive.


Movement Disorders | Clinical Neurology News | NeurologyLive

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAIC 2025

CMSC 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1.125rem

Clinical

SUP-22-NRD0184 - /clinical/movement-disorders

 movement disorders clinical focus page is a source for all the latest news regarding the clinical care of patients with Parkinson disease, essential tremor, Huntington disease, dystonia, ataxia, and more. This page features podcasts, videos, and news about FDA actions, study and clinical trial findings, clinical guideline updates, and interviews with experts in the clinical care of movement disorders.

 to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

In this episode, "Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management" Alexa Dessy, MD, clinical assistant professor in movement disorders at Jefferson Health, shares a comprehensive look at modern-day care strategies for patients with Parkinson disease and other movement disorders. Dessy discusses the foundational role of detailed history-taking, exam-based observation, and phenomenology in diagnosing complex conditions, along with the growing utility of genetic and imaging tools. She also explains the challenges of managing nonmotor symptoms—like sleep disturbance, fatigue, and constipation—and how lifestyle strategies and interdisciplinary collaboration are often as vital as medication. Lastly, she emphasizes the importance of clear and compassionate communication with patients and families as neurology becomes increasingly therapeutic.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Eisai Showcases Promising 4-Year Data for Alzheimer Therapy Lecanemab at AAIC 2025

IHL-42X to Enter Phase 3 Trials for Obstructive Sleep Apnea Following Positive Phase 2 Data

FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine

 – How movement disorder diagnosis is approached through history, physical exam, and phenomenology

 – What makes certain movement disorder cases complex and how diagnostics like genetics and imaging are used

 – How nonmotor symptoms in Parkinson’s (fatigue, constipation, sleep) are managed with lifestyle strategies

 – Approaching therapeutic communication and expectation-setting with patients and families

 to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Alexa Dessy, MD. [LISTEN TIME: 17 minutes]

Episode 147: Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management

In this episode, "Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease," Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center, discusses the phase 3 exPDite-2 trial evaluating bemdaneprocel, an investigational cell therapy for Parkinson disease (PD). Pahwa explains the rationale behind cell replacement therapy as a means to restore dopamine production, outlining the progression from fetal tissue implants to stem cell–derived dopaminergic neurons. He details key elements of the study design, including patient selection criteria, trial endpoints, and long-term goals. Reflecting on decades of research in this space, he emphasizes the potential impact of a one-time, hardware-free surgical option and how this novel approach could complement or shift the current treatment landscape. While many questions remain, Pahwa highlights the promise of bemdaneprocel as a next-generation option in Parkinson care.

BTK Inhibitor Fenebrutinib Demonstrates Long-Term Suppression of MS Activity in Open-Label Extension

REGENXBIO Reports Positive Phase 1/2 Data for Higher Dose of RGX-202 in Duchenne Muscular Dystrophy

NewAmsterdam Pharma Reports Positive Topline Data of Alzheimer Agent Obicetrapib from Phase 3 BROADWAY Trial

 – Mechanism and rationale behind bemdaneprocel as a dopaminergic cell therapy

– Key design considerations for conducting a registrational phase 3 cell therapy trial

 – Trial structure, eligibility criteria, and ongoing patient recruitment

 – Significance of reaching phase 3 with a cell therapy in Parkinson disease

 – Future role of cell therapy within the Parkinson disease treatment landscape

 – Unique aspects of the exPDite-2 trial and what sets it apart from earlier efforts

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Rajesh Pahwa, MD. [LISTEN TIME: 15 minutes]

Episode 143: Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease

 podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

This special episode episode, "What Apomorphine Infusion Approval Means for Parkinson Disease Care" covers the recent approval of Supernus Pharmaceuticals' agent SPN-830, marketed as Onapgo, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson disease (PD). SPN-830, which has been available in Europe for several years, was approved based on data from the TOLEDO study (NCT02006121), a randomized, double-blind study in which treatment with the device was associated with a difference of –1.89 hours per day of OFF time for patients with PD in comparison with placebo. To gain greater insights on how this approval impacts the clinical and patient communities, 

 sat down with movement disorder experts Stuart Isaacson, MD, director of the Parkinson’s disease and movement disorders center of Boca Raton, and Rajesh Pahwa, MD, the Laverne and Joyce Rider professor of neurology at the University of Kansas Medical Center. The duo discussed the significance of the approval, considerations for patient selection with the treatment, as well as the studies supporting its safety and efficacy. In addition, the pair provided context on how this approval, along with other recent approvals in PD, speak to the progress the clinical and research community has made over the years.

For more of NeurologyLive's coverage of SPN-830 for Parkinson disease, head here:

FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment

 – Significance of SPN-830's approval and impact on PD community

 – Considerations for treatment selection with SPN-830, conversations with families

 – TOLEDO study, supportive efficacy and safety data for SPN-830

 – Expanding PD treatment options and overviewing recent progress in research

 podcast. Be sure to leave a rating and review for the show. Thanks for listening!

REFERENCES
1. Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease. News Release. Supernus. Published February 4, 2025. Accessed March 26, 2025. https://ir.supernus.com/news-releases/news-release-details/supernus-announces-fda-approval-onapgotm-apomorphine

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Stuart Isaacson, MD; and Rajesh Pahwa, MD. [LISTEN TIME: 17 minutes]

Special Episode: What Apomorphine Infusion Approval Means for Parkinson Disease Care

In this episode, "Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test," Russ Lebovitz, MD, PhD, chief executive officer and cofounder of Amprion, discussed the company's SAAmplify-aSYN biomarker test, a first-in-class qualitative laboratory developed test and the only seed amplification assay available to aid in the diagnosis of synucleinopathies such as Parkinson disease (PD) and multiple system atrophy (MSA). Lebovitz provided insight on the new technology and its remarkable accuracy in identifying underling a-synuclein pathology using fluorescence changes. He gave a complete overview of the notable study published in 

 that further tested and validated the assay among a heterogenous group of synucleinopathies. Furthermore, he provided clinical context on the feasibility of the assay, the potential for clinical use, and the continued validation needed. 

Axsome to Submit NDA for AXS-05 in Alzheimer Agitation Following Positive Phase 3 Trials

FDA Clears IND for Trial Assessing Gene Therapy SGT-212 in Friedreich Ataxia

FDA Grants Fast Track Designation to Anti-Tau Therapy Posdinemab

 – Overviewing mechanistic function of SAAmplify-aSYN biomarker test, its purpose, and how it came about

 – Results from the published study; ways the fluorescence-based amplification method could distinguish MSA from PD and Lewy body dementia

 – Therapeutic feasibility of the assay in clinical settings and the next steps in validation

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Russell Lebovitz, MD, PhD. [LISTEN TIME: 22 minutes]

Episode 132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test

Episode 131, "Neurology Unwrapped: 2024's Most Intriguing Conversations" compiles some of the most compelling conversations from 

 podcast episodes throughout 2024. These discussions spotlight groundbreaking research and advancements in neurology that are propelling the field forward. The 

 team also explored the impact of several newly FDA-approved therapies, offering clinicians valuable insights into what these treatments mean for patient care and their practical use in the clinic. Featured in this week’s episode, in order of appearance, are:


, staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, gives an overview on the new 2024 McDonald criteria to diagnose multiple sclerosis (MS), which was presented at the 

40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis

, executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, on the changing and exciting advances in Alzheimer disease therapeutics, as well as the discontinuation of aducanumab, the first approved antiamyloid therapy.

Lessons Learned in Alzheimer Drug Development

, vice chair of the American Academy of Sleep Medicine's Practice Guidelines Task Force, discusses the newly revised guidelines for restless legs syndrome, including the latest updates in literature and changes to clinical care.

Implications of the 2024 AASM Guidelines for Restless Legs Syndrome

, a movement disorder specialist at the Marcus Neuroscience Institute of Baptist Health, provided clinical perspective on the use of the Syn-One diagnostic test for patients with Parkinson disease.

Utilizing the Syn-One Test to Diagnose Parkinson Disease

, an assistant professor of neurosurgery at Mayo Clinic Arizona, spoke at the 2024 American Epilepsy Society Annual Meeting on cell therapy approaches for epilepsy, the challenges the clinical community faces, and the outlook for the future.

The Promise Behind Cell Therapy Approaches in Epilepsy

, a senior scientist at Sunnybrook Research Institute, gives insight on educating the next generation of neuromuscular and electrodiagnostic (EDX) practitioners, and the major differences in how this generation of medical students learn relative to previous ones.

Adapting Neuromuscular and Electrodiagnostic Medicine Education for Modern Learners

 – Ontaneda on the incorporation of new biomarkers into the 2024 McDonald Criteria for multiple sclerosis.

 – Kremer on the lessons learned from drug development, including antiamyloid treatments, and initial reaction to the discontinuation of aducanumab for AD. 

 – Berkowski on the outlook of treating and preventing restless legs syndrome going forward using the newly updated American Academy of Sleep Medicine treatment guidelines. 

 – Husain-Wilson on the function of the Syn-One test for Parkinson disease, its applicability, and how it may distinguish patients with PD from other synucleinopathies.

 – Parker on the promise and thought process behind stem cell approaches for drug-resistant epilepsy, including the different types of cell methods being tested. 

 – Robinson on the distinct differences in learning styles based on generation, the importance of adaptive teaching, and the new approaches educators in neuromuscular and electrodiagnostic medicine can take. 

Mind Moments®, a podcast from NeurologyLive®, brings you a review of 2024, with insights from Daniel Ontaneda, MD, PhD; Ian Kremer; Andy Berkowski, MD, PhD; Sameea Husain-Wilson, DO; Jonathan Parker, MD, PhD; and Lawrence Robinson, MD. [LISTEN TIME: 25 minutes]

Neurology Unwrapped: 2024’s Most Intriguing Conversations

In this episode, "Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy" we're joined by Daniel Claassen, MD, MS, a professor of neurology and chief of the Behavioral and Cognitive Neurology Division at Vanderbilt University Medical Center, who offered his insight on phase 1/2 data that was recently presented at the 

International Parkinson and Movement Disorder Society (MDS) Congress

 on ATH434, an investigational drug in development from Alterity Therapeutics for multiple system atrophy (MSA). He dove into the therapy's mechanism of action and the currently known safety profile and considerations for its use, as well as the next steps in advancing care for patients with MSA as a whole.

FDA Removes Partial Hold for Myotonic Dystrophy Agent AOC 1001

FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy

FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment

 – Overviewing the conduct of the phase 1/2 studies

 – Notable findings from data presented at MDS

 – Current unmet needs for patients with MSA

International Parkinson and Movement Disorders Society Congress (MDS)

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Claassen, MD, MS. [LISTEN TIME: 14 minutes]

Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy

In this episode, Sameea Husain-Wilson, DO, a movement disorder specialist at the Marcus Neuroscience Institute of Baptist Health, provided clinical perspective on the use of the Syn-One diagnostic test for patients with Parkinson disease (PD). She gave an overview of how the test is utilized in clinic, ways to interpret results, and the right personnel needed to ensure an accurate diagnosis. In addition, she provided clarity on the role of alpha-synuclein in PD, the advances in research in this area, and how the test incorporates this prominent biomarker. Furthermore, Husain-Wilson detailed some of the next steps in further optimizing the test in clinical settings, highlighting the importance of other non-movement disorder specialists who will play a major role in the diagnostic evaluation of future patients with PD.

FDA Approves Eli Lilly's Donanemab for Early Symptomatic Alzheimer Disease

Buntanetap Improves Motor, Nonmotor and Cognitive Symptoms of Parkinson Disease in Phase 3 Study

Gene Therapy AMT-130 Slows Huntington Disease Progression in Interim Phase 1/2 Trials

 – Step by step process on how Syn-One test is used; considerations after process is done

 – How the test differentiates PD from other neurodegenerative disorders

 – Value and role in assessing alpha-synuclein in PD

 – Ways to further optimize Syn-One going forward

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sameea Husain-Wilson, DO. [LISTEN TIME: 19 minutes]

Episode 119: Utilizing the Syn-One Test to Diagnose Parkinson Disease

To watch the video series component of this episode, click here.

3:20 Preclinical start of Parkinson’s disease

5:00 Alpha-synuclein in Parkinson’s disease

The neurology experts discuss the importance of early and accurate diagnosis of Parkinson’s disease, the role of alpha-synuclein in the diagnosis of synucleinopathies and approaches to implementing screening protocols in clinical practice.

Movement Disorders

Latest News